Alzheimer's drug could help fight antibiotic resistance


Tuesday, 24 November, 2020


Alzheimer's drug could help fight antibiotic resistance

Australian researchers have found that an experimental Alzheimer’s disease treatment is proving effective at treating some of the most persistent, life-threatening antibiotic-resistant bacteria.

Researchers from The University of Queensland (UQ), The University of Melbourne and Griffith University have discovered that the drug, called PBT2, is effective at disrupting and killing Gram-negative bacteria, which cause infections such as pneumonia, bloodstream infections and meningitis. Their results, published in the journal Science Translational Medicine, suggest that the metal transport drug may offer a last line of defence against some of the world’s most difficult-to-treat superbugs.

“The emergence of antibiotic-resistant superbugs is an urgent threat to human health, undermining the capacity to treat patients with serious infection,” said UQ Professor Mark Walker. Alternative strategies to treat such multidrug-resistant bacteria are therefore urgently needed.

“Led by UQ’s Dr David De Oliveira, our team hypothesised that by using this experimental Alzheimer’s treatment to disrupt the metals inside these bacteria, we would also disrupt their mechanisms of antibiotic resistance,” Prof Walker continued.

“This was shown to be the case, with the Alzheimer’s drug — combined with the antibiotic polymyxin — successfully tackling antibiotic-resistant superbugs like Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli.”

Griffith University’s Professor Mark von Itzstein, from the Institute for Glycomics, said the new treatment was effective and offered a range of other benefits.

“Based on its use as an experimental Alzheimer’s treatment, there’s been a significant amount of solid science done on this drug already,” Prof von Itzstein said.

“We know, for example, that clinical studies of PBT2 show that it is safe for use in humans.

“And, given that we’ve been able to combine it with the antibiotic polymyxin to treat polymyxin-resistant bacteria, we may be able to make other now-ineffective antibiotics become effective again for treating infectious diseases.

“This could resharpen, so to speak, some of the weapons we thought we’d lost in our fight against antibiotic-resistant bacteria.”

The University of Melbourne’s Associate Professor Christopher McDevitt, from The Peter Doherty Institute for Infection and Immunity, said the drug has already proved effective beyond the petri dish.

“Animal studies show that the combination of polymyxin and PBT2 kills polymyxin-resistant bacteria, completely clearing any infection,” Assoc Prof McDevitt said.

“Hopefully in the not-too-distant future, people will be able to access this type of treatment in the clinic.

“New techniques are critical in addressing this building threat to human health, and this treatment is an additional weapon in our arsenal to fight the accelerating threat of antibiotic resistance.”

Image caption: UQ’s Dr David De Oliveira analysing samples in the lab.

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Childhood neglect affects brain development over generations

Early life experiences can have an outsized effect on brain development and neurobiological...

Scientists discover new mutations in the 'immunity gene'

An infant's odd case of rare encephalitis has led researchers to discover never-before-seen...

Three molecular subtypes of Alzheimer's identified

Researchers at the Icahn School of Medicine at Mount Sinai have identified three major molecular...


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd